| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (NCT05394740) | National Cancer Center Hospital East | 2022-06-06 |
| GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (NCT05419362) | Genome & Company | 2022-04-07 |
| Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (NCT05111626) | Amgen | 2022-03-14 |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (NCT05052801) | Amgen | 2022-03-07 |
| First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (NCT05156866) | TORL Biotherapeutics, LLC | 2022-02-02 |
| Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma (NCT05034887) | National Cancer Center Hospital East | 2022-01-31 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors (NCT04683939) | BioNTech SE | 2022-01-18 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) (NCT05002127) | ALX Oncology Inc. | 2022-01-15 |
| iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT04808791) | AHS Cancer Control Alberta | 2021-10-27 |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma (NCT05008783) | Akeso | 2021-09-17 |
| A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) (NCT04933227) | Hoffmann-La Roche | 2021-08-06 |
| Folfox+Irinotecan+Chemort In Esophageal Cancer (NCT04656041) | Massachusetts General Hospital | 2021-06-29 |
| Real-world Data (RWD) of Ramucirumab Plus Paclitaxel (NCT04915807) | Hallym University Medical Center | 2021-06-01 |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. (NCT04850729) | Nanfang Hospital, Southern Medical University | 2021-05-25 |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (NCT04704934) | Daiichi Sankyo | 2021-05-21 |
| Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (NCT04499924) | Seagen Inc. | 2021-03-22 |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989) | Arcus Biosciences, Inc. | 2021-03-19 |
| A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (NCT04661150) | Hoffmann-La Roche | 2021-03-12 |
| Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (NCT04762953) | University of California, Irvine | 2021-02-18 |
| Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma (NCT03986502) | Fred Hutchinson Cancer Center | 2021-01-22 |
| Esophageal cAncer Screening Trial (NCT04609813) | Changhai Hospital | 2021-01-01 |
| HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (NCT04447352) | Krankenhaus Nordwest | 2020-12-17 |
| NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (NCT04615013) | M.D. Anderson Cancer Center | 2020-11-23 |
| Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (NCT04581473) | CARsgen Therapeutics Co., Ltd. | 2020-10-23 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection (NCT04510285) | Memorial Sloan Kettering Cancer Center | 2020-08-10 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies (NCT04361708) | University of Chicago | 2020-05-08 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (NCT03739801) | University of Southern California | 2020-04-06 |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (NCT04263870) | Sichuan University | 2020-03-01 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| Registry Platform Gastric/Esophageal Cancer (SAPHIR) (NCT04290806) | iOMEDICO AG | 2019-12-04 |
| A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer (NCT04161781) | Memorial Sloan Kettering Cancer Center | 2019-11-12 |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma (NCT04089904) | University of Chicago | 2019-10-11 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (NCT03979131) | Vall d'Hebron Institute of Oncology | 2019-08-22 |
| Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer (NCT04018872) | Dallas VA Medical Center | 2019-06-24 |
| Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction (NCT03986385) | Hebei Medical University | 2019-06-01 |
| Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (NCT03604991) | National Cancer Institute (NCI) | 2019-05-03 |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (NCT03966118) | P. C. Thuss-Patience | 2019-04-01 |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma (NCT03802591) | CStone Pharmaceuticals | 2019-03-28 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma (NCT03852251) | Akeso | 2019-01-18 |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (NCT03735290) | Mendus | 2019-01-14 |
| TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (NCT03686488) | H. Lee Moffitt Cancer Center and Research Institute | 2018-12-20 |
| Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (NCT03760822) | Federation Francophone de Cancerologie Digestive | 2018-11-16 |
| A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer (NCT03707028) | Elevar Therapeutics | 2018-10-01 |
| Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (NCT03421288) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2018-09-14 |
| Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors (NCT03511222) | Washington University School of Medicine | 2018-09-11 |
| OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma (NCT03429816) | University Hospital Heidelberg | 2018-04-15 |
| Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847) | M.D. Anderson Cancer Center | 2018-02-09 |
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction (NCT03349866) | Hebei Medical University | 2017-11-30 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer (NCT03196232) | George Albert Fisher | 2017-09-13 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers (NCT03122548) | Aduro Biotech, Inc. | 2017-08-14 |
| Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer (NCT02530437) | M.D. Anderson Cancer Center | 2017-03-07 |
| A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer (NCT02898077) | Eli Lilly and Company | 2017-03-02 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063) (NCT03019588) | Merck Sharp & Dohme LLC | 2017-02-16 |
| Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer (NCT02962063) | Memorial Sloan Kettering Cancer Center | 2016-11-01 |
| Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer (NCT02830594) | City of Hope Medical Center | 2016-10-05 |
| Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer (NCT02891447) | M.D. Anderson Cancer Center | 2016-09-01 |
| Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (NCT02730546) | Mayo Clinic | 2016-06-24 |
| Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis (NCT02628951) | Samsung Medical Center | 2016-05-26 |
| Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis (NCT02589496) | Samsung Medical Center | 2016-03-26 |
| A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies (NCT02572687) | Eli Lilly and Company | 2016-02-19 |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer (NCT02514551) | Eli Lilly and Company | 2015-10-12 |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02539225) | Eli Lilly and Company | 2015-10-05 |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer (NCT02443883) | Eli Lilly and Company | 2015-07-07 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) (NCT02370498) | Merck Sharp & Dohme LLC | 2015-05-11 |
| Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma (NCT03083613) | Chinese Academy of Medical Sciences | 2015-05-01 |
| Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer (NCT02389751) | M.D. Anderson Cancer Center | 2015-04-10 |
| A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) (NCT02335411) | Merck Sharp & Dohme LLC | 2015-02-03 |
| A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (NCT02314117) | Eli Lilly and Company | 2015-01-20 |
| MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038) | Millennium Pharmaceuticals, Inc. | 2014-12-01 |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (NCT02128243) | AIO-Studien-gGmbH | 2014-09-01 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma (NCT02193594) | Peking University | 2014-01-01 |
| Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections (NCT02077673) | Rigshospitalet, Denmark | 2013-12-01 |
| MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer (NCT02007148) | International Group of Endovascular Oncology | 2013-11-01 |
| Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (NCT01962246) | Hebei Medical University | 2012-02-01 |
| Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (NCT01196390) | National Cancer Institute (NCI) | 2011-02-14 |
| Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT01379807) | Grupo Gallego de Investigaciones Oncologicas | 2010-12-01 |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma (NCT00964080) | Mebiopharm Co., Ltd | 2009-05-01 |
| Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT00763646) | McGill University | 2007-04-01 |
| Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (NCT00515411) | Memorial Sloan Kettering Cancer Center | 2006-10-23 |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France (NCT02307812) | Eli Lilly and Company | |